StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck pharmaceutical Sales — Latin America share of Pharmaceutical revenue (%) (%)

Form 8-K Supplemental Table 3c / 3b (Pharmaceutical Geographic Sales)

Latest, FY2025
4.4%
Period ended Dec 31, 2025
Change on a year earlier
-0.3 pts
4.7% in FY2024
History
10 years
Since FY2016
Sources
10
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPharmaceutical Sales — Latin America share of Pharmaceutical revenue (%) (%)Year on yearSource
FY2025Dec 31, 20254.4%-0.3 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
FY2024Dec 31, 20244.7%+0.4 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2023Dec 31, 20234.3%+0.7 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
FY2022Dec 31, 20223.6%-0.1 ptsForm 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
FY2021Dec 31, 20213.7%0.0 ptsForm 8-K (tm235007d1_ex99-1.htm, filed 2023-02-02) ↗
FY2020Dec 31, 20203.7%-0.9 ptsForm 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗
FY2019Dec 31, 20194.6%+0.9 ptsForm 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
FY2018Dec 31, 20183.7%0.0 ptsForm 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2017Dec 31, 20173.7%-0.2 ptsForm 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
FY2016Dec 31, 20163.9%–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Cite this data

StockData. (2026). Merck Pharmaceutical Sales — Latin America share of Pharmaceutical revenue (%) (%), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/pharma_geo_latinamerica_share

See every metric in the Merck KPI table. Data updated Oct 26, 2026.